In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...
Zacks.com on MSN
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...
If you've ever wondered how mustard powder differs from that jar of mustard in your fridge, we've got you covered, as well as ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback